Clinical Trial

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

Study acronym: HEM-DOAC

Recruiting

Record status

This record was last updated December 26, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-25.

Trial Details

NCT Number	NCT07270263
Lead Sponsor	Medical University of Gdansk
Conditions	Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease, VTE (Venous Thromboembolism), PE - Pulmonary Embolism, Hematologic Malignacies
Enrollment	100 participants
Start Date	2024-11-22
Primary Completion	2026-04-30 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-26